-
公开(公告)号：US20230018729A1
公开(公告)日：2023-01-19
申请号：US17409639
申请日：2021-08-23
IPC分类号： C07K16/24 , A61P1/04 , C12Q1/6883 , A61P1/00 , C07K16/28
摘要： Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
-
公开(公告)号：US20230272098A1
公开(公告)日：2023-08-31
申请号：US18316811
申请日：2023-05-12
发明人： Laurens KRUIDENIER , Mahyar SABRIPOUR , Jeffry D. Watkins , Cindy T. DICKERSON , Rafael ROJAS , Matthew REISSMAN , Patricia MCNEELEY , Janine BILSBOROUGH , Dermot P. MCGOVERN , Dalin LI
IPC分类号： C07K16/28 , C12Q1/6883 , C12Q1/6851 , A61P1/04
CPC分类号： C07K16/2875 , C12Q1/6883 , C12Q1/6851 , A61P1/04 , C12Q2600/156 , C12Q2600/106 , C07K2317/52 , C07K2317/565 , C07K2317/24 , C07K2317/92 , C07K2317/76
摘要： Provided are methods, systems, and kits for selecting a subject for treatment with an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression based on a presence of one or more genotypes associated with a positive therapeutic response to the inhibitor of TL1A. Also provided are methods, systems and kits for detecting the one or more genotypes described herein.
-
公开(公告)号：US20230272061A1
公开(公告)日：2023-08-31
申请号：US18168519
申请日：2023-02-13
IPC分类号： C07K16/24 , A61P1/04 , C12Q1/6883 , A61P1/00 , C07K16/28
CPC分类号： C07K16/241 , A61P1/00 , A61P1/04 , C07K16/2875 , C12Q1/6883 , A61K2039/505 , C12Q2600/156
摘要： Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
-
公开(公告)号：US20210101988A1
公开(公告)日：2021-04-08
申请号：US17118441
申请日：2020-12-10
摘要： Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
-
-
-
搜索结果
4 条记录 (耗时 0.017 秒)
